BioSig Strengthens Marketing and Sales Teams, Appoints National Account Executives to Scale Commercial Growth
August 30 2022 - 9:37AM
- Company increases sales efforts and strategy, adds new
National Account Executives to accelerate commercial
growth
- Strengthens marketing team with new marketing and
communications programs highlighting competitive market
advantage
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the
"Company"), a medical technology company advancing
electrophysiology workflow by delivering greater intracardiac
signal fidelity through its proprietary signal processing platform,
today announced that it has expanded its marketing and sales teams
to scale and support the national commercial rollout of
its PURE EP™ System.
BioSig recently doubled the size of its sales organization, with
plans of tripling it before the fourth quarter of this year. The
Company appointed a new team of National Account
Executives who will be strategically located throughout
the U.S. to support and accelerate sales growth and adoption of the
PURE EP™ System. The new sales executives will expand the Company’s
growing commercial pipeline, as it continues to see an increase in
medical centers entering into 60-day evaluation agreements for its
novel signal processing technology.
Additionally, BioSig has expanded its marketing team, with
investment in top-tier industry talent that will help drive and
enhance the Company’s brand equity and awareness to better reflect
the Company’s values. These new efforts include a fully integrated
marketing and communications strategy that will support the
commercial team and should provide the tools to increase BioSig’s
competitive position in the market.
“As a growing enterprise, we are dedicated to sourcing,
developing, and retaining the best talent for our company. I view
our recent investment in our commercial, sales, and marketing teams
as a complimentary catalyst for BioSig’s new commercial strategy
and longterm growth. We are thrilled to have attracted these
outstanding industry leaders, and look forward to leveraging their
wealth of knowledge and expertise,” said Gray Fleming, Chief
Commercialization Officer, BioSig Technologies, Inc.
About BioSig TechnologiesBioSig Technologies is
a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company's first product, PURE EP™ System, is a novel signal
processing and acquisition platform designed to extract advanced
diagnostic and therapeutic data that enhances physician workflow
and increases throughput. PURE EP™ was engineered to address the
limitations of existing EP technologies by empowering physicians
with superior signals and actionable insights. The Company is in a
national commercial launch of the PURE EP™ System. The technology
is in regular use in some of the country’s leading centers of
excellence, including Mayo Clinic, and Texas Cardiac Arrhythmia
Institute at St. David’s Medical Center.
Clinical data acquired by the PURE EP™ System in a multi-center
study at centers of excellence including Texas Cardiac Arrhythmia
Institute at St. David’s Medical Center was recently
published in the Journal of Cardiovascular Electrophysiology and is
available electronically with open access via the Wiley Online
Library. Study results showed 93% consensus across the blinded
reviewers with a 75% overall improvement in intracardiac signal
quality and confidence in interpreting PURE EP(T.M.) signals over
conventional sources.
Forward-looking StatementsThis press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) market conditions and the Company’s intended
use of proceeds, (ii) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (iii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iv) difficulties in
obtaining financing on commercially reasonable terms; (v) changes
in the size and nature of our competition; (vi) loss of one or more
key executives or scientists; and (vii) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024